Does releasing Wolbachia‐carrying mo

Active case finding (ACF) looks for people with tuberculosis in communities who would not otherwise present to health facilities. In doing so, ACF can improve the number of people diagnosed and treated for tuberculosis (TB), as well as reduce onward transmission.

During February 2024, the CIDG contributed to one review in Issue 2, 2024 of the Cochrane Database of Systematic Reviews, and one publication in Clin

Is favipiravir useful in treating people with COVID‐19?

Since 2022, Cochrane has bestowed new lifetime and emeritus memberships, recognizing the extraordinary contributions of individuals who have made an exceptional, long-standing contribution to Cochrane’s work and leadership. Three Cochrane Infectious Diseases Group (CIDG) Editors were recognized at the 2023 Cochrane Colloquium for their outstanding work.

During January 2024, the CIDG contributed to one new Cochrane protocol and one new review published in Issue 1, 2024 of the Cochrane Database of Systematic Reviews, and one publication in

Key messagesTwo doses of the whole‐cell plus recombinant vaccine (WC‐rBS vaccine (Dukoral)), with or without a booster dose, reduces cases of cholera for two years.

The weeks of 2023 continue to fly by! As the end of 2023 approaches, the Cochrane Infectious Diseases Group (CIDG) editorial base in Liverpool conveys thanks to its readers, authors, referees, Editors, and READ-It Partners for their continued support to the CIDG’s work. In this newsletter we reflect on the past 12 months at the CIDG.

During November 2023, the CIDG contributed to one new Cochrane protocol and one updated review in Issue 11, 2023 of the Cochrane Database of Systematic Reviews.

Is the combination of nirmatrelvir plus ritonavir effective for treating or preventing COVID‐19?Key messagesNirmatrelvir/ritonavir (Paxlovid) is evaluated for the treatment of coronavirus disease 2019 (COVID‐19).